A study of eOD-GT8 60mer mRNA Vaccine (mRNA-1644) in HIV-1 uninfected adults
The company International AIDS Vaccine Initiative is enrolling patients into the clinical trial investigating A Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644).
A Phase 1 Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644) in HIV-1 Uninfected Adults in Good General Health.
2 doses eOD-GT8 60mer mRNA Vaccine (100µg), 2 vaccinations, 8 weeks apart No control group. There is no blinding and no randomization in this open label study
The trial is designed to enroll male and female 18 Years to 50 Years and is being conducted in the Center for Family Health Research, Kigali, Rwanda; Aurum Tembisa Clinical Research Centre, Johannesburg, South Africa.
The study start date is May 26, 2022.
This page provides a more detailed overview of this clinical trial: https://ichgcp.net/clinical-trials-registry/NCT05414786 or clinicaltrials.gov/ct2/show/NCT05414786
.
